mobile header
Home > Doctors > Dr Shinto Francis Thekkudan

Dr Shinto Francis Thekkudan

Senior Consultant & Chief

Haematology, Haemato-Oncology And BMT

  • BMH Kozhikode

  • BMH Kannur

Book an Appointment
Share Profile
Dr Shinto Francis Thekkudan

Dr. Shinto Francis Thekkudan is the Chief and Senior Consultant in Clinical Hematology, Hemato-Oncology, and Bone Marrow Transplantation at Baby Memorial Hospital, Calicut. He has more than 15 years of medical experience with advanced training from premier institutions in India and abroad, including CMC Vellore, SGPGI Lucknow, Rajiv Gandhi Cancer Institute, MD Anderson Cancer Center (Houston), University Hospitals Seidman Cancer Center (Cleveland), Cleveland Clinic (Ohio), and Mayo Clinic (Rochester).

He is an expert in managing complex hematological disorders, including leukemias, lymphomas, myeloma, and benign hematological conditions, with a strong focus on bone marrow transplantation and cellular therapies such as CAR T cell and BiTE therapy. Dr. Shinto has received several prestigious international fellowships, research awards, and recognitions, and has presented his work at multiple national and global hematology conferences.

OP Timings: Monday, Tuesday, Wednesday & Friday 10:00 AM - 03:00 PM

Phone- 7012907744 | WhatsApp -7012078573

  • MBBS – Government Medical College, Thrissur (2007)
  • MD (General Medicine) – Government Medical College, Calicut (2013)
  • DM (Clinical Hematology) – Sanjay Gandhi Post Graduate Institute, Lucknow (2017)
  • Fellowship in Bone Marrow Transplantation – Rajiv Gandhi Cancer Institute & Research Centre, New Delhi (2019)
  • IACA Fellowship – MD Anderson Cancer Center, Houston, Texas, USA (2018)
  • ASH – Visitor Training Program Scholarship – University Hospitals Seidman Cancer Center, Cleveland, Ohio, USA (2019)
  • Observership – Department of Hematology/Oncology, Mayo Clinic, Rochester, MN, USA (2024)
  • MRCP (UK) – Part 1 (2014)
  • Senior Consultant & Chief – Clinical Hematology & Hemato-Oncology, Baby Memorial Hospital, Calicut (2019–Present)
  • Attending Consultant – Hemato-Oncology & Bone Marrow Transplant Unit, Rajiv Gandhi Cancer Institute, Delhi (2017)
  • Senior Resident – Clinical Hematology, SGPGI, Lucknow (2017)
  • Senior Registrar – Clinical Hematology, Christian Medical College, Vellore (2014)
  • Senior Resident – Department of General Medicine, Government Medical College, Calicut (2013–2014)
  • Medical Officer – PHC Thrikkur, Thrissur (2009)
  • Hemato-Oncology (Leukemias, Lymphomas, Myeloma)
  • Bone Marrow Transplantation (Allogeneic, Haploidentical, Matched Unrelated Donor)
  • Cellular Therapies (CAR T Cell Therapy, BiTE Therapy)
  • Benign Hematological Disorders
  • Management of hematological emergencies and complications
  • Promising Oncologist 2024 – TIMES NETWORK
  • Young Hematology Scholar Award 2024 – Summit on Hematological Cancers, Nashville, USA
  • ASH – Visitor Training Program Award 2019 – University Hospitals Seidman Cancer Center, Ohio
  • Indo-American Cancer Association Fellowship 2018 – MD Anderson Cancer Center, Houston, USA
  • LEUKA – European School of Hematology Scholarship 2018 – John Goldman Conference on CML, Miami, USA
  • Multiple Best Poster and Thesis Awards (ICON, EHA-ISHBT, HEMATOCON, PGIMER, SGPGI)
  • Gold and Silver Medals during MBBS (Anatomy, Obstetrics & Gynecology)
  • Indian Medical Association (IMA)
  • Cochin Hematology Group (Past Treasurer, 2022–2024)
  • Author of more than 20 research papers in international and national journals, including the American Journal of Hematology, Advances in Cell & Gene Therapy, British Journal of Haematology, Annals of Hematology, Indian Journal of Hematology & Blood Transfusion, and BMH Medical Journal.

  • Research focus on leukemias, multiple myeloma, stem cell transplantation, CAR T cell therapy, and novel targeted agents.

  • Presented abstracts and oral papers at global conferences including ASH, EHA, ISHBT, and John Goldman CML Conference.

    Key research projects

    • Ikaros deletions in Acute Lymphoblastic Leukemia
    • Kinase Domain Mutations and Nilotinib Response in CML
    • REACH-3 Trial – Ruxolitinib in Chronic GvHD
  • Real Experiences. Genuine Care.

    Related Doctors

    View More